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INTRODUCTION 
 
Medicinal plants have become of interest 
in  recent  years  due  to  their  prospects  in 
meeting  the  health  needs  of mankind.
[1-4] 
The  long  history  and  widespread  use  of 
herbal medicines has always been seen as 
evidence  to  this  fact.
[] Recently  however, 
these  prospects  have  meant  that  herbal 
medicines and other natural products are 
being subjected to a lot of scrutiny.
[6] The 
major  issue  of  concern  with  these 
medicines  have  been  with  their  quality, 
safety and efficacy.
[7-8]  
ABSTRACT 
Background:  The  widespread  use  of  herbal  medicines  in  recent  years 
means that issues concerning their quality, safety and efficacy need to be 
answered. In the current study, the polyherbal formulation EAF-2011 used in 
the  Centre  for  Scientific  Research  into  Plant  Medicine,  Mampong-
Akwapemfor the management of superficial mycoses was evaluated for its 
quality and safety. Aim: The study sought to evaluate the quality and safety 
of  the  product  in  the  management  of  superficial  mycoses.  Method:  The 
method of standardisation using the basic phytochemical screening and the 
thin  layer  chromatography  procedures  was  used.  The  stability  was  also 
assessed using the thin layer chromatography, an antimicrobial assay and 
the physicochemical properties of the product. A safety evaluation of the 
product was also performed using a skin sensitisation and chronic toxicity 
test  in  male  Sprague-Dawley  rats.  Results:  The  product  demonstrated 
stability during the study period of one year as results obtained from the thin 
layer chromatography, physicochemical and biological assay did not indicate 
any  significant  change  in  characteristics.  Alkaloids,  phenols,  flavonoids, 
sterols and triterpenes were detected in the product. Three spots obtained 
by  the  thin  layer  chromatography  were  shown  to  be  ideal  for  use  as 
analytical markers for the product. Haematological, biochemical, urine and 
histopathological data at the end of the study did not indicate any adverse 
effect from the herbal treatments. Conclusion: The study thus showed the 
ointment to be safe for the management of superficial mycoses. 
 
Key  words:  Analytical  markers,  chronic  toxicity,  polyherbal  formulation, 
safety, standardisation, superficial mycoses 
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The evaluation of the quality of medicinal 
products  is  very  essential  as  they  are 
affected  by  factors  that  include  seasonal 
changes, harvesting time, cultivation sites, 
post-harvesting processing, adulterants or 
substitutes  of  raw  materials  and 
procedures in extraction and preparation.
[9] 
These factors are also known to also have 
implications on the safety and efficacy of 
resultant products.
[9-10]  
 
The  availability  of  data  in  the  area  of 
quality, safety and efficacy is very scarce 
for majority of medicinal products in use.
[9] 
A reason assigned for this limitation is the 
lack  of  adequate  and  accepted  research 
methodologies  for  evaluating  natural 
products.
[11]  However,  steps  have  been 
taken by several agencies like the World 
Health  Organisation  (WHO)  and  the 
International  Union  of  Pure  and  Applied 
Chemistry  (IUPAC)  aimed  at  addressing 
these  challenges.
[12-14]  Significant  among 
these  interventions  are  the 
recommendations  for  the  standardisation 
of  all  medicinal  products.
[14]  Suggestions 
have  been  made  for  the  preclinical 
screening  of  natural  products  for  safety 
and efficacy especially when there is the 
absence  of  guidelines  for  carrying  out 
actual clinical assessment.
[12]  
 
In  the  current  study  the  polyherbal 
formulation  labelled  EAF-2011  from  the 
Centre  for  Scientific  Research  into  Plant 
Medicine,  Mampong-Akwapem  and  used 
in  the  management  of  superficial  fungal 
diseases  was  evaluated.  The  product 
formulated with five plants has no previous 
documentation on its quality and safety.  
 
METHODOLOGY 
 
Plant used in the study 
The  plants  in  the  formulation  were  the 
dried leaves of Alchorneacordifolia(Schum. 
&Thonn.)Muell.Arg.  (Euphorbiaceae),  the 
dried  leaves  of  Psidiumguajava(Linn) 
(Mrytaceae),  the  dried  whole  plant  of 
Tridaxprocumbens(Linn) (Asteraceae), the 
dried  stem  bark  of 
Zanthoxylumzanthoxyloides(Lam) 
(Rutaceae)  and  the  dried  fruit  buds  of 
Eugenia  caryophyllata(Thumb) 
(Mrytaceae). 
 
Plant collection and authentication 
The  plants  used  were  sourced  from 
Mampong-Akwapem  and  its  environs  in 
November  and  December,  2010  except 
Eugenia  caryophyllata  which  was 
purchased  from  some  commercial 
collectors.  The  plants  were  authenticated 
by  Mr.  Ofori-Lartey,  botanist  at  the  Plant 
Development  Department,  Centre  for 
Scientific  Research  into  Plant  Medicine 
(CSRPM),  Mampong-Akwapem.  Voucher 
specimen  number  was  allocated  (Table 
1.0)  and  the  specimen  was  deposited  at 
the herbarium of the CSRPM. 
 
Plant preparation 
The various plant materials were air-dried 
in  a  cool,  dry  place  under  shade  for  2 
weeks at temperatures between 23ºC and 
27ºC. The materials were pulverized using 
a hammer mill through 2mm screen. Each 
powdered plant material was extracted by 
macerating  1kg  of  the  powdered  plant 
material in 5 L of 70 % (
v/v) ethanol for 3 
days  and  then  filtered.  The  ethanol  was 
recovered  using  the  rotary  evaporator 
(Buchi™  R210)  and  the  fluid  extract 
evaporated on a water bath over 72hrs. 
 
Composition of the product 
The  individual  herbal  extracts  were 
combined  according  to  the  established 
recipe  used  by  the  CSRPM  in  the 
formulation of the product. 
 
Standardisation of the product 
The  standardisation  of  the  product 
involved  two  methods:  the  basic 
phytochemical screening and the thin layer 
chromatography.  In  the  basic 
phytochemical screening, the ointment, the 
total crude extracts and the individual plant 
materials  were  each  screened  for  the 
presence  of  alkaloids,  saponins, 
flavonoids,  sterols/triterpenes, 
anthracenosides  and  cyanogenic 
glycosides using methods described.
[16-17] 
 
The  thin  layer  chromatography  was  also 
performed for the ointment, the total crude 
extracts and the plant materials according 
to  the  methods  prescribed.
[18-19] The  total 
crude extract (TC) and the ointment were 
extracted in 70 % (
V/v) of ethanol for three 
days.  The  aqueous  fraction  from  this 
extraction was obtained by evaporating the 
ethanol  using  the  rotary  evaporator.  This 
aqueous fraction  was then extracted with 
ethyl  acetate  in  a  separating funnel  (1:2) 
(
v/v). The ethyl acetate fraction was spotted 
for the TLC on precoated silica gel 60 F 254 
plates (Merck). Detection was done using Dickson et al.: Polyherbal product EAF-2011 and superficial mycoses 
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an Ultraviolet Lamp at 365nm and 254 nm 
and  anis  aldehyde  detecting  reagent  at 
ambient temperature. 
 
Stability studies of the product 
The stability of the product was tested by 
employing  the  methods  of  the  thin  layer 
chromatography,  an  antimicrobial  assay 
and  assessing  the  physical  properties  of 
the  ointment.  These  studies  were 
conducted at the baseline month 0, month 
6, month 9 and month 12.
[20]  
 
Thin layer chromatography 
The  thin  layer  chromatography  was 
performed  according  to  the  guidelines 
described under the standardisation of the 
product. 
 
Antimicrobial assay 
The agar well diffusion method was used 
for the antimicrobial assay as described in 
the B.P, (1988).An amount of 16g of the 
ointment  was  dissolved  in  100mLof  20% 
dimethylsulphoxide  (DMSO).  Petri  dishes 
of  100mm  were  filled  with  25mLof 
sabouraud  agar  for  the fungal  organisms 
and  25mLof  Mueller  Hinton  for  the 
bacterial organisms. The plates were filled 
to a depth of 4mm and allowed to solidify. 
Each  plate  was  then  flooded  with  the 
pathogenic micro-organism and the plates 
were allowed drying at room temperature 
for  one  hour.  A  sterilised  borer  of  an 
internal diameter of 4mm was used to bore 
holes  in  the  media.  The  herbal  products 
were dispensed into the bored holes. The 
filled  petri  dishes  were  kept  in  the 
refrigerator for 6 hrs to allow absorption of 
the  extract  into  the  media  and  then 
incubated at 27
oC for 72hrs for the fungal 
organisms  and  38
oC  for  24hrs  for  the 
bacterial  organisms.  DMSO  was  used  as 
the negative control for all test organisms 
while fluconazole was used as the positive 
control  for  the  fungal  organisms  and 
chloramphenicol  for  the  bacterial 
organisms. After the incubation period, the 
diameter  of  each  zone  of  inhibition  was 
measured in millimetres with a metre rule. 
The measure  of the  zone  of inhibition  at 
each period of assay was compared and 
used as an indicator of the stability of the 
product. 
 
Organoleptics 
The  organoleptic  features:  colour,  odour 
and  consistencyof  the  product  were 
observed over the duration of the stability 
studies.  Observations  were  made  by  two 
independent investigators.  
 
pH 
An  amount  of  1g  of  the  ointment  was 
dispersed  in  100mL  of  distilled  water  by 
vigorous  shaking  and  warming  over  a 
water  bath  to  melt  the  ointment.  The 
mixture  was  allowed  to  cool  under  room 
temperature to separate the insoluble wax 
from  the  aqueous  phase.  The  insoluble 
wax was then decanted and the pH of the 
aqueous  fraction  determined  using  the 
digital  pH  meter  (Cyberscan  pH  310; 
EutechInst).
[18] 
 
Preclinical chronic toxicity testing 
of the product 
Skin sensitisation and chronic toxicity was 
conducted  for  the  product to identify  any 
possible toxic effects. All experiments were 
performed  according  to  the  protocol 
described by Nyarko et al. and conducted 
in accordance with accepted principles for 
laboratory  animal  use  and  care  (EU 
directive of 1986: 86/609/EEC).
[18] 
 
Animals 
Male  Sprague-Dawley  rats  (200-250g) 
were used for the study. Animals were fed 
on powdered feed from Ghana Agro Food 
Company  (GAFCO)  Tema,  Ghana  and 
also  allowed  free  access  to  sterilized 
distilled water. 
 
Skin sensitization 
The hair on the lateral portion of albino rats 
(about  9cm
3)  was  trimmed  and  shaved 
with a razor blade. The rats were divided 
into  5  groups  (n=5).  One  group  was 
injected  intradermally  with  0.1mL  of  5% 
(
w/v)  of  the  highest  dose  of  the  ointment 
dissolved in glycerol. The control was also 
received an intradermal injection of 0.1Ml 
glycerol.  The  duration  of  the  resultant 
swelling  was  observed,  as  well  as  any 
ulceration  that  appeared  subsequently. 
The various dosage concentrations of the 
ointment were also applied topically to the 
three  (3)  groups  of  rats  and  the  animals 
were observed daily for 6 months for any 
ulceration,  irritation  and/or  inflammation. 
The  last  group  did  not  receive  any 
treatment and served as the control. 
 
Chronic toxicity 
Four groups of five rats each were kept in 
three different metal cages. Group 1 was 
kept as control and they received sterilised Dickson et al.: Polyherbal product EAF-2011 and superficial mycoses 
Int J Med Biomed Res 2013;2(2):91-102 
 
  94   
   
water  and  no  treatment  for  six  weeks. 
Groups 2, 3 and 4 were treated with 2% 
(
w/w),  5  %  (
w/w)  and  10  %  (
w/w)  of  the 
ointment  respectively.  Baseline  readings 
for the liver, kidney and urine parameters 
were taken. These were then repeated at 
the 1st, 3rd and 6th months. 
 
Haematological,  biochemical  and  urine 
analyses 
Blood  samples  were  obtained  by  tail 
bleeding  (at  baseline,  1st,  3rd  and  6th 
month)  into  Eppendorf  tubes  without 
anticoagulant.  Samples  were  centrifuged 
for 5 mins (Denley BS 400, England) and 
the serum stored at -40
oC for biochemical 
analysis.  Blood  samples  were  also 
collected for haematological analysis. 
 
Haematological  analysis  was  done  using 
Haema-Screen  18  (Hospitex  Diagnostics, 
Italy) according to the established protocol. 
Serum biochemical analysis was also done 
using  protocols  from  Cypress  Diagnostic 
Kits  (Belgium)  with  a  semi-automated 
blood  chemistry  analyser,  photometer 
4040.  Urine  samples  were  also  collected 
and  analysed  for    specific  gravity,  pH, 
glucose,  bilirubin,  ketones,  proteins, 
urobilinogen,  nitrates,  blood  and 
leucocytes  using  urine  reagent  strip 
UroColor™  10  (Standard  Diagnostic  Inc., 
Korea). 
 
Histology 
Two rats from each group were euthanized 
after 6 months of treatment. Biopsies were 
taken from  the liver, spleen, kidneys and 
skin.  The  skin  biopsy  was  obtained  from 
the area where the ointment was applied. 
Specimen  was  preserved  in  10% 
formaldehyde  solution  (formalin).  Tissues 
were embedded in paraffin wax, sectioned 
into  uniform  thickness  of  10  μm  and 
stained  with  hematoxylin  and  eosin. 
Sectioned tissues were evaluated under a 
microscope  for  any  morphological 
changes. 
 
Statistical analysis 
One-way  analysis  of  variance  (ANOVA) 
and  independent  sample  t-test  was 
conducted  to  determine  statistical 
significance.  Statistical  tests  were 
performed  with  Graphpad  Prism  software 
version 5.0 at an α-level of 5%.  
 
 
 
RESULTS 
 
Standardisation of the product 
The results of the phytochemical screening 
showed  the  presence  of  alkaloids, 
phenols,  sterols  and  triterpenes  and 
flavonoids in the product. The results are 
compared  to  that  of  the  individual  plant 
extracts  and  the  total  crude  extract  in 
Table  2.  No  differences  were  observed 
between  the  plant  extract,  total  crude 
extract  and  the  ointment.  The  thin  layer 
chromatograph  provided  three  analytical 
markers for the product (Figure 1). The Rf 
values of the spots were A (0.87), B (0.64) 
and C (0.57).  
 
Table1:  Voucher  specimen  number  of 
plant materials used 
Plant Material  Voucher 
Specimen 
Number 
Alchorneacordifolia  CSRPM 368 
Psidiumguajava  CSRPM 50 
Tridaxprocumbens  CSRPM 256 
Zanthoxylumzanthoxyloides  CSRPM 330 
Eugenia caryophyllata  CSRPM 
001CM 
 
 
Stability studies of the product 
Thin layer Chromatography 
The chromatographic finger print obtained 
for the ointment and the total crude extract 
was  repeated  over  a  year  period.  The 
values  obtained  for  each  period  of  time 
were not different (Figure 2).The baseline 
and  after  one  year  of  study for  both test 
samples  showed  the  ointment  and  the 
crude  extracts  to  be  stable  as  the  spots 
obtained at the end of the study were not 
different from that obtained at the start of 
the study. Similar Rf values were recorded 
A (0.87), B (0.64) and C (0.57). 
 
Antimicrobial assay 
The  antimicrobial  assay  of  the  ointment 
against  three  fungal  pathogens: 
Micosporumcanis,  Trichophytonrubrum, 
and  Candida  albicans  and  one  bacterial 
pathogen  (Staphylococcus  aureus) 
produced similar results over the one year 
study  period  (Table  3).  The  differences 
observed  in  the  readings  were  not 
significantly  different  at  the  start  of  the Dickson et al.: Polyherbal product EAF-2011 and superficial mycoses 
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study  and  after  one  year.  The  ointment 
also  showed  appreciable  activity  against 
the bacterial pathogen. 
 
Organoleptic characters and pH 
The study of the organoleptic characters of  
the  ointment  at  the  baseline  showed  the 
ointment  to  be  dark  brown  in  colour, 
aromatic in odour, smooth with no lumps 
or  grittiness  in  consistency.  These  same 
observations  were  made  subsequently  in 
the following period of study as shown in 
Table 4. A marginal change in pH values 
was recorded at the end of the study. The 
pH was recorded at the start of the study 
and during the study. This is also recorded 
in Table 4.  
 
 
Table 2: Results of the phytochemical screening of the various samples 
Plant Extract 
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Alchorneacordifoli
a  -  +  -  +  +  -  - 
Eugenia 
caryophyllata  -  +  +  -  +  +  - 
Psidium. Guajava  -  +  -  +  +  -  - 
Zanthoxylumzanth
oxyloides  +  +  +  -  +  -  - 
Tridaxprocumbens  +  +  -  +  +  -  - 
Total Crude 
Extract  +  +  +  -  +  -  - 
Ointment 
(EAF-2011)  +  +  +  -  +  -  - 
Key: (-) Absent; (+) Present 
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Table 3: Zones of inhibition produced by the ointment (EAF-2011) over one year period 
Month  Microsporum 
canis 
Trichophyton 
rubrum 
Candida 
albicans 
Staphylococcus 
aureus 
0  12.7 (0.22)  13.3 (0.12)  10.3(0.56)  20.3(0.01) 
3  12.3 (0.31)  13.0 (0.32)  10.0(0.45)  19.7(0.20) 
6  13.3 (0.25)  14.0 (0.00)  10.3(0.34)  20.0(0.47) 
12  13.2 (0.88)  13.8 (0.71)  10.2(0.67)  19.8(0.84) 
Results are Mean ±SD; n=3 
 
Table 4: Organoleptic characters and pH of the ointment during the stability study 
 
Figure 1: Chromatographic fingerprint obtained for the individual plant extracts. Tridaxprocumbens (TP), 
Alchorneacordifolia (AC), Zanthoxylumzanthoxyloides (ZZ), Psidiumguajava (PG), Eugenia caryophyllata 
(EG), Total crude extract (TC) and the ointment (OM). Solvent system: ethyl acetate: petroleum ether 
(1:4). The Rf values obtained for the spots were A: 0.87, B: 0.64, C: 0.57. 
 
 
Month 
 
Colour  Odour  Consistency  pH 
0  Dark 
Brown  Aromatic  No grittiness or 
lumps observed 
5.42 @ 29.2 
⁰C 
3  Dark 
Brown  Aromatic  No grittiness or 
lumps observed 
5.29 @ 30.2 
⁰C 
6  Dark 
Brown  Aromatic  No grittiness or 
lumps observed 
5.67 @ 30.4 
⁰C 
12 
 
Dark 
Brown  Aromatic  No grittiness or 
lumps observed 
5.71 @ 29.4 
⁰C Dickson et al.: Polyherbal product EAF-2011 and superficial mycoses 
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Table 5: Effect of ointment on haematological parameters at termination 
Haematology    Treatment 
  Control  2%  5%  10% 
NEU(mm
3)  13.37 ±0.98  14.57  ± 2.41  18.03 ± 0.69  28.53 ± 11.79 
LYM(mm
3)  81.93 ±0.81  56.37 ± 20.34  56.27 ± 19.62  66.90 ± 11.36 
MON(mm
3)  3.93 ± 0.29  29.67 ± 23.97  27.83 ± 22.54  3.40   ± 1.32 
EOS(mm
3)  0.30 ± 0.00  2.13    ± 1.83  3.00   ± 2.65  0.70   ± 0.15 
BAS(mm
3)  0.47 ± 0.07  0.47    ± 0.03  0.47   ± 0.07  0.47   ± 0.07 
RBC(mm
3)  8.68 ± 0.16  5.82     ± 2.71  5.86   ± 2.78  8.01   ± 0.64 
HB(g/dl)  16.50 ±0.23  13.58   ± 2.62  14.01 ± 2.79  15.10  ±1.30 
HCT(%)  48.70 ±0.45  36.90  ± 10.10  37.67 ± 10.94  44.00 ± 4.11 
MCV(µm
3)  56.00 ±1.00  53.10  ± 1.99  52.77 ± 3.23  54.67 ± 0.88 
MCH(pg)  19.03 ±0.33  32.30 ± 13.35  31.30 ± 11.85  18.87 ± 0.09 
MCHC(g/dl)  33.90 ±0.20  29.63 ± 4.82  29.30 ± 5.30  34.43 ± 0.32 
RDW(%)  10.83 ±0.58  10.87 ± 0.15  18.47 ± 7.82  10.80 ± 0.46 
PLT(mm
3)  614.00±128.58  587.67 ±219.85  772.00 ± 47.32  696.67 ± 44.64 
MPV(µm
3)  5.80 ± 0.12  6.27  ± 0.48  5.87  ± 0.07  5.97  ± 0.26 
WBC(mm
3)  12.00 ± 0.56  11.50 ± 1.93  11.43 ± 0.81  11.80 ± 0.90 
Results are Mean ± S.E.M; n=5 
Key: HB - Haemoglobin, HCT - Haematocrit, BAS - Basophils, LYM - Lymphocytes,MCHC - Mean 
Corpsular Haemoglobin Concentration, MCH - Mean Corpsular Haemoglobin, MCV - Mean Corpsular 
Volume, MPV - Mean Platelet Volume, MON – Monocytes, NEU - Neutrophils, PLT - Platelets, RBC - 
Red Blood Cells, RDW - Red Blood Cell Distribution Width, WBC - White Blood Cells. No significant 
difference was observed were observed between the test and control for all parameters in all the 
treatment groups (p<0.05). Implying the ointment has no effect on the blood cells. 
 
 
Table 6: Effect of the ointment on the liver and kidneys after treatment 
    Treatment 
  Control  2%  5%  10% 
Kidney Function         
UREA(mmol/l)  3.43 ± 0.30  3.13  ± 0.30  2.93  ± 0.07  2.90  ± 0.10 
CREATININE 
(mmol/l)  36.07 ± 3.33  25.07 ± 2.93  44.75 ± 6.93  28.33 ± 3.31 
Liver Function         
ALBUMIN(g/L)  30.85 ± 2.08  32.35 ± 1.01  32.82  ± 1.39  32.70 ± 0.87 
ALT(u/L)  104.67±0.91  98.67 ± 3.72  99.67 ±13.17  87.10 ± 8.98 
AST(u/L)  139.45 ±8.51  170.14 ± 
11.08 
132.07 ± 
28.09  147.43±25.87 
GGT(u/L)  1.20  ± 0.23  1.10   ± 0.15  1.43   ± 0.35  2.60   ± 0.62 
ALP(u/L)  4.67  ± 0.88  4.67   ± 0.33  3.33   ± 0.88  4.00  ± 0.58 
Results are Mean of ±S.E.M; n= 5 
Key:  ALT  –  Alanine  Transaminase,  AST  –  Aspartate  Transaminase,  GGT  –  Gamma 
GlutamylTransferase,  ALP  –  Alkaline  Phosphatatse.  No  significant difference  was  observed  (p<0.05) 
were  observed  between  the  test  and  control  animals for all  parameters in  all  the  treatment  groups. 
Implying the ointment has no harmful effect on the liver and kidneys. Dickson et al.: Polyherbal product EAF-2011 and superficial mycoses 
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Table 7: Effect of the ointment on urine parameters at termination of treatment 
Urine Parameter    Treatment 
  Control  10%  2%  5% 
Urobilinogen  -  -  -  - 
Glucose  -  -  -  - 
Ketones  -  -  -  - 
S. G  1.024  1.022  1.023  1.012 
Blood  -  -  -  - 
pH  7.0  7.2  7.3  7.3 
Proteins  ++  +  ++  + 
Nitrites  -  -  -  - 
Key: (-): negative; (+): present in moderate quantities; (++) present in large quantities. There was no 
significant difference between the controls and test meaning there is no adverse effects on the kidneys. 
 
Table 8: Post treatment effect of EAF-2011 on the organ weights (weight to body ratio) of rats 
Organ  Control  2 %  5 %  10 % 
Kidney  2.29 ± 0.16  2.24 ± 0.57  2.16 ± 0.24  2.21± 0.84 
Spleen  0.71± 0.64  0.71 ± 0.15  0.63 ± 0.11  0.65 ± 0.18 
Liver  12.61 ± 1.71  12.19 ± 2.90  10.50 ± 0.85  11.29 ± 2.82 
Results are Mean ± SEM; n=5 
 
             
Figure 2: The chromatograph of the ointment and total crude extract at the baseline and the end of the 
study.Solvent system: Ethyl acetate: Petroleum ether (1:4).The Rf values obtained for the spots were A: 
0.87, B: 0.64, C: 0.57. 
Key: Ointment at the start (OM-1), Ointment after a year (OM-F), Total crude extract at the start (TC-1) 
and Total crude extract after a year (TC-F). Dickson et al.: Polyherbal product EAF-2011 and superficial mycoses 
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Figure 3: A photomicrograph comparing the longitudinal section of the skin from the animals treated with 
the 10 %EAF-2011 (Left) and the control (Right). Magnification x 400 
Figure 4: A photomicrograph of the transverse section of the liver from the animals treated with the 10 
%EAF-2011 (Left) and the control (Right). Magnification x400 
 
Figure 5: A photomicrograph of the transverse section of the kidney from the Sprague-Dawley 
rats treated with the 10 %EAF-2011 (Left) and the control (Right). Magnification x400 Dickson et al.: Polyherbal product EAF-2011 and superficial mycoses 
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Figure 6: A photomicrograph comparing the spleen from Sprague-Dawley rats treated with the 10 % 
EAF-2011 (Left) and the control (Right). Magnification x 400 
 
Preclinical  chronic  toxicity  tests  of  the 
product 
Skin sensitivity testing 
The  skin  sensitivity  test  using  the  male 
Sprague-  Dawley  rats  showed  no  dermal 
irritation  in  the  form  of  ulcerations  was 
observed  during  the  6  months  of 
treatment. Subcutaneous papule that was 
formed  after  intradermal  injection  of  the 
ointment  dissolved  in  glycerol  resolved 
without  any  ulceration  after  72hrs  of 
observation as in the control treatment. 
 
Chronic toxicity studies 
The results from the chronic toxicity study 
indicated that the ointment did not cause 
any  significant  change  in  the 
haematological,  biochemical  and  urine 
parameters  after  6  months  of 
administration.  The  results  of  the 
haematological,  biochemical  and  urine 
parameters are shown in Table 5, 6 and 7 
respectively. 
 
Histology 
The gross features of the organs isolated 
after termination were detected to have no 
abnormalities.  No  significant  differences 
were  observed  in  the  organ  weights 
between  the  control  and  the  herbal 
treatments  (Table  8).  Microscopic 
examination of the tissues did not indicate 
any  histopathological  changes  to  the 
tissues  sampled.  The  skin  epidermis, 
dermis and adnexal tissues were regular in 
pattern.  The  spleen  had  regular  red  and 
white  pulps  with  some  haemosiderin 
deposition  which  was  considered  as 
physiological. In the kidneys the glomeruli, 
tubules  and  interstitium  were  normal. 
There was no indication of an inflammation 
or  necrosis.  The  liver’s  portal  tracts, 
hepatocytes  and  sinusoids  were  normal 
with  the  absence  of  inflammation  or 
fibrosis.  There  was  also  no  hepatocyte 
degeneration.  These  features  were 
identified in the Whitfield, 2 %, 5 % and 10 
% herbal treatment. Samples micrographs 
from histopathology are shown in Figures 
3-6. 
 
DISCUSSION 
 
The  quality  evaluation  of  medicinal 
products has become a key component in 
the assessment of herbal medicines. The 
value of these studies for natural products 
cannot  be  overemphasised  as  the 
variability  in  medically  active  constituents 
in these products has implications on the 
therapeutic  effects  produced  by  them.
[21] 
Standardisation of all natural remedies has 
been  touted  as  a  solution  to  this 
challenge.
[21] 
 
The basic phytochemical screening of the 
product EAF-2011 indicated the presence 
of secondary metabolites like the alkaloids, 
phenols,  flavonoids,  sterol  and 
triterpenesin the product. The results apart 
from  providing  a  standard,  also 
corroborates  the  indication  given  to  the 
product as some compounds belonging to 
this  class  of  secondary  metabolites 
detected  have  shown  some  antifungal Dickson et al.: Polyherbal product EAF-2011 and superficial mycoses 
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activity. Ursolic acid a triterpene found in 
Psidiumguajava has been reported for its 
antifungal  activity  against  Candida 
albicans.
[20]  Quercetin  and  kaempferolall 
flavonoids previously identified in Eugenia 
caryophyllata,  Psidiumguajava  and 
Tridaxprocumbenshave also showed some 
antifungal  activity.
[23]  Alkaloids  like  the 
berberine  and  furoquinoline  have  been 
reported  to  be  active 
againstTrichophyton,Epidermophyton, 
Micosporum and Candida species isolated 
from  some  individuals  with 
dermatophytosi.
[24-25]  These  two  alkaloids 
are  noted  to  be  present  in 
Zanthoxylumzanthoxyloidesone  of  the 
plants  in  the  product.  The  activity  of  the 
product  can  hence  be  attributed  to  the 
presence of these secondary metabolites. 
 
Despite  the  importance  of  the  basic 
phytochemical  screening  in 
standardisation,  the  use  of  multiple 
methods in this process provides a more 
reliable  guarantee  about  the  quality  of 
products.
[26]  A  confirmation  to  this 
statement  has  been  made  by  some 
authors  who  have  suggested  methods  of 
standardisation  that  have  been  classified 
under  the  broad  categories  of  physical, 
botanical,  chemical  and  biological 
standardisation.
[26-27]  These  suggestions 
make  the  results  of  the  thin  layer 
chromatography,  antimicrobial  assay  and 
the  physicochemical  properties  employed 
during the stability study also relevant for 
the process of standardisation.
[27] Also, the 
markers  obtained  by  the  thin  layer 
chromatography;  shown  to  be  mostly 
phenolic  compounds  by  their  colour,  can 
be considered as analytical markers for the 
product  based  on  their  stability  and 
adequate  detection  with  little  interference 
(Figures 1and 2).
[28] The markers from the 
individual plant can be used for monitoring 
the quality of plant materials collected and 
during the manufacturing process as they 
were  shown  on  the  chromatograph  to 
contribute  to  the  markers  in  the  final 
product.
[28] 
 
With  the  safety  of  herbal  medicinal 
products  considered  as  relevant  as  any 
other  procedures  in  the  drug  evaluation 
process, it is important that the product did 
not  induce  any  change  in  the 
haematological,  biochemical  and  urine 
parameters which by extension means that 
the  product  was  not  likely  to  have  any 
harmful  effect  on  the  human  subjects 
(Tables 6 to 8).
[14] The skin sensitivity ruled 
out  any  irritations  and  immune  response 
that may be elicited on the administration 
of  the  product  a  finding  that  was  further 
confirmed  on  the  histopathological 
examination of the sampled skin tissue by 
the  absence  of  immuno-modulatory 
structures  like  the  mast  cells.
[29]  These 
results  are  important  despite  the  product 
having  some  history  of  use  in  humans 
because the reliance on data from folkloric 
knowledge for safety has its own limitation 
such as the inability to detect toxic effects 
that develop in long term usage and those 
that occur as a result of hypersensitivity to 
the products.
[30] 
 
CONCLUSION 
 
The  results  from  the  study  showed  the 
product, EAF 2011, to be of good quality 
(stable)  over the  study  period  as  well  as 
safe for use under the specified conditions 
of the experiment.Despite the fact that only 
one mammalian specie (rats) was used in 
the study for the safety, the long history of 
use  enables  a  less  stringent  assessment 
to  be  made  on  the  product.  Also,  data 
obtained  from  the  studyprovides  a 
monograph  for  the  product  to  guarantee 
quality in subsequent products. 
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